Neuste Beiträge aus: Solos (SNDY) - Biggest runner of the year - MK$400.000

Solos Endoscopy and Opko Health Benefit From Booming Medical Equipment and Supplies Industry

The Paragon Report Provides Equity Research on Solos Endoscopy & Opko Health

NEW YORK, NY, Mar 22, 2012 (MARKETWIRE via COMTEX) -- Medical device and technology stocks have performed admirably in 2012. Year to date, the iShares Dow Jones U.S. Medical Devices Index Fund is up more than 15 percent. While investor sentiment appears positive at the moment, politicians and consumers are calling for greater oversight into the industry. Moreover, a medical device tax, which became law nearly 2 years ago as part of the Patient Protection & Affordable Care Act, is set to go into effect on January 1, 2013. The Paragon Report examines the outlook for companies in the Medical Equipment & Supplies industry and provides equity research on Solos Endoscopy Inc. (PINKSHEETS: SNDY) and Opko Health Inc. (NYSE Amex: OPK). Access to the full company reports can be found at: www.paragonreport.com/SNDY
www.paragonreport.com/OPK

A recent Consumer Reports poll shows overwhelming public support for strong medical device safety oversight. The poll was released as House and Senate Committees have issued draft legislation to reauthorize the statute governing medical devices and at a time when the FDA's process for reviewing new implants has come under increased criticism. The House Energy and Commerce Health Subcommittee's draft bill would weaken device safety oversight and should be rejected by Congress, according to Consumers Union, the policy and advocacy arm of Consumer Reports.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Medical Equipment & Supplies industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Most medical devices don't require proof that they have been clinically tested and found to be safe and effective before they are cleared for distribution or sale by the Food and Drug Administration.

While much of the House calls for less oversight, a bipartisan foursome has crafted a Senate bill that would arm the FDA for stronger oversight of medical devices while also pushing it into action. The legislation would require the agency to issue a final Unique Device Identifier (UDI) rule by the end of 2012 and add medical devices to the FDA's Sentinel postmarket surveillance initiative.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

SOURCE: Paragon Financial Limited

Copyright 2012 Marketwire, Inc., All rights reserved.
**********************************************************************
As of Sunday, 03-18-2012 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated an UPTREND on 09-12-2011 for OPK @ $4.27.

For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2012 Comtex News Network, Inc. All rights reserved.

-0-

SUBJECT CODE: Financial Services:Commercial and Investment Banking
Financial Services:Investment Services and Trading

Antwort auf Beitrag Nr.: 42.928.045 von hadesitem am 20.03.12 11:31:36schau einfach mal auf www.otcbb.com ,wo es hingeht kann keiner sagen ,wir werden es aber bald wissen

wenn ich viele Ignorebalken sehe...kanns nur "gerdass " sein...das heißt dann wiederum für mich ...Finger weg...und das sehr weit......Empfehlungen des Kollegen seither knapp 100 K US$ verhauen....

cup and handle

seit gegrüßt leute,
ich bin durch dig101 auf euch aufmerksam geworden.......erst mal glückwunsch euch allen.......ich muß mal rein lesen ob das was handfestes ist.
vileicht lohnt sich ein einstieg obwohl ich bei neomedia wieder einmal den ausstieg verpasst habe......50% waren ja zu wenig gewinn....
wer lust hat kann mir ja einen 3 zeiler zum thema schreiben

http://us2.campaign-archive1.com/?u=e1d484af62a96bc40cb4accb…

Antwort auf Beitrag Nr.: 42.926.051 von drchirom am 19.03.12 22:16:24ein Dr.Wagner ist im Kloster

http://www.kloster-bronnbach.de/showpage.php?Ansprechpartner…

Antwort auf Beitrag Nr.: 42.926.051 von drchirom am 19.03.12 22:16:24ich bin schon reich
mehr Geld schadet allerdings jetzt auch nicht mehr

Antwort auf Beitrag Nr.: 42.699.228 von workstock am 04.02.12 11:36:12und neue Endoscope Steri Serie gestarted, CE Mark pending for Europa, und Einstieg in die Tier Medizin Veterinaer medicin, 4th quartal finance wird gut abschneiden, Bis zum Ende des Jahres 15 Cent

Dr Matthias Wagner
Kansas City USA

Antwort auf Beitrag Nr.: 42.921.498 von gerdass am 19.03.12 09:34:55Ich lebe in Kansas City und bin im Investorshub SNDY forum LONG AND STRONG!!!

Go SNDY der Stock wird uns reich machen

http://www2.barchart.com/quotes/stocks/SNDY

http://ih.advfn.com/p.php?pid=staticchart&s=NO%5ESNDY&p=0&t=…

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

Antwort auf Beitrag Nr.: 42.916.656 von gerdass am 16.03.12 21:45:01Solos' SteriTAP™ instruments are also approved to immediately receive the CE Mark, which will allow the product to be marketed in those countries where the CE Mark is required, once Solos Endoscopy receives its proper certifications

Antwort auf Beitrag Nr.: 42.699.206 von workstock am 04.02.12 11:29:25Solos (SNDY) - Biggest runner of the year

Today 5d 1m 3m 1y 5y 10y



Solos Endoscopy to Launch New SteriTAP™ Endoscopic Instrument Line
New Product Line Positioned to Capitalize on Worldwide Demand for Sterile Endoscopy
BOSTON, March 16, 2012 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company will be launching a new endoscopic instrument line, SteriTAP™. Solos' SteriTAP™ Instruments are designed to be the ultimate sterile "take a part" endoscopic instruments of its kind and will be marketed and sold worldwide by Solos Endoscopy.

Solos' SteriTAP™ instruments are also approved to immediately receive the CE Mark, which will allow the product to be marketed in those countries where the CE Mark is required, once Solos Endoscopy receives its proper certifications. According to Reportlinker, the demand for endoscope services is increasing due to an increase in the aging and chronically ill population worldwide. Advancements in endoscopic technologies and inclusion of various types of lighting sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market. Endoscopy procedures have become highly effective in the diagnosis, treatment, and management of cancer patients. Many now consider endoscopy to have become the gold standard for cancer diagnosis and treatment, as well as for many other medical conditions.

There are other reasons that minimally invasive surgical (MIS) procedures like endoscopy are gaining ground in the overall medical arena. Endoscopic procedures, in general, have a lower cost than their counterparts in traditional surgery. In some cases, the patient only needs light sedation as opposed to full anesthesia. Reduced post surgery monitoring time is required for patients undergoing endoscopic procedures. Finally, there is usually a significantly reduced period the patient has to stay in the hospital along with reduced ancillary costs associated with a post-surgical hospital stay.

The SteriTAP™ Instrument line will be added to the Solos Endoscopy product line assortment, which are all featured on the Company's website: http://www.solosendoscopy.com.

"Solos continues to invest its resources in developing new endoscopic instruments to offer a greater selection of products for our customers," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the Pink OTC Markets (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:

Amanda Segersten,

Rsegersten@Solosendoscopy.com

SOURCE Solos Endoscopy, Inc.





Source: PR Newswire (March 16, 2012 - 10:27 AM EDT)

News by QuoteMedia

http://ih.advfn.com/p.php?pid=staticchart&s=NO%5ESNDY&p=0&t=…

ein Stinky pinky vom Feinsten:
zuerst ein 150 million retirement Paket ankündigen
dann im gleichem Zeitraum O/S von 304 million auf 440 millions
Aufblasen

ouch !

so gap zu bei sndy

dafür ist der umsatz einfach noch zu hoch ,es befinden sich ja nur 130 mio im float ,lassen wir uns morgen mal überraschen was die amis machen die fliegen auf jedenfall auf sndy ,im investorhub sind die platz 2

Antwort auf Beitrag Nr.: 42.777.462 von dig101 am 20.02.12 15:00:04Im letzten Anstieg hätten bei diesen Umsätzen theoretisch alle Stücke gedeckt werden können!

Jan 31, 2012 463 -99.88 17,497,967 1.00 No No
Jan 13, 2012 398,913 273,128.10 2,898,872 1.00 No No
Dec 30, 2011 146 239.53 10,150,901 1.00 No No
Dec 15, 2011 43 -96.93 5,363,183 1.00 No No
Nov 30, 2011 1,402 -98.77 3,642,520 1.00 No No
Nov 15, 2011 114,227 253,737.78 5,584,313 1.00 No No



http://www.otcmarkets.com/stock/SNDY/short-sales



die frage ist wie will man die wieder decken ,der float beträgt gerade mal 139 mio und wenn man jetzt wirklich 463 mio decken will ,das wird nicht fkt


Market Value $243,921 Updated 12/23/2011
Shares Outstanding 379,897,709 Updated 02/10/2012
Float 139,556,215 Updated 09/30/2011
Authorized Shares 500,000,000 Updated 09/30/2011
Par Value $0.001

Allerdings steht dort 0,0008% Short of Free Float, das sind die 47TsdStk umgerechnet auf die 57Mio Shares lt Bloomberg.
Auch wenn die Shares nicht stimmen, ist das sehr gering.

Antwort auf Beitrag Nr.: 42.777.278 von dig101 am 20.02.12 14:23:15Wann sind diese Shorts aufgebaut worden?
Ich schätze vor dem neuesten Kursanstieg, da die Daten immer leicht veraltet sind?!

Wenn dem so wäre, und das Mng. haut per MG neue News raus, geht das Ding durch die Decke.

Short Interest 463
Shares Short (% prior month) 217.1233%



wie seht ihr das sind da wirklich welche mit 463 mio short


http://www.bloomberg.com/quote/SNDY:US/key-statistics


das wäre ja der wahnsinn und kaum zu decken in den usa ist man schon auf platz 1 im investorhub

Antwort auf Beitrag Nr.: 42.763.351 von Wohnwunsch am 16.02.12 20:26:44die frage ist nur ist der zock schon vorbei ,im investorhub ist solos auf platz 2


man hatte schonmal 350 mio aut. shares bloss da stand man wesentlich höher ,siehe 2010